Karen Kelly, MD

Articles

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Dr. Kelly on Preliminary Data With Neoadjuvant Immunotherapy in Lung Cancer

July 28th 2020

Karen Kelly, MD, discusses encouraging preliminary data with neoadjuvant immunotherapy in lung cancer.

Dr. Kelly on Challenges With Starting Immunotherapy in Lung Cancer

March 31st 2020

Karen Kelly, MD, discusses challenges with choosing when to start immunotherapy in patients with lung cancer.

Dr. Kelly on Determining Second-Line TKI in Lung Cancer

November 14th 2019

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

Dr. Kelly on the Toxicity Profile in CheckMate-227 in NSCLC

September 20th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

August 26th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Kelly on the JAVELIN Solid Tumor Trial

April 22nd 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.